This combination can bring differentiated value to the patient

$STSS we cut cost Less materials Less waste Less time to administer Less liability to nurse or patients Less lawsuits Less is more with Sharps Let's go

$STSS we cut inflation to the injectable drug markets Lower manufacturing footprint Lower Waste Less time to administer drug Less liability with dual safety to nurse and patients Less drug waste to big pharma cost and entire medical industry

Key advantages of prefillable syringe systems address contamination issues for the broader healthcare market, improving drug shelf life while reducing unnecessary packaging, and providing best-in-class solutions to get drugs to patients more efficiently.

Prefilled syringes drug delivery is convenient for those patients that require parenteral administration of drugs on a daily/weekly basis and long-term treatment.

$STSS Sharps Ultra-Low waste syringe combats #inflationary pressures for all injectable medications plus added safety reducing liability claims to both the nurse and patients .

$STSS Sharps Ultra-Low waste syringe combats #inflationary pressures for all injectable medications plus added safety reducing liability claims to both the nurse and patients .

$STSS $STSS Sharps Ultra-Low waste syringe combats #inflationary pressures for all injectable medications plus added safety reducing liability claims to both the nurse and patients .

Several hospitals, diagnostic centers, and general practitioners employ safety prefilled syringes for drug delivery, as these offer less overfills and better safety to patients.

The easing of COVID-19 restrictions enabled Novo’s practitioners to provide patients with additional in-person services.

The easing of COVID-19 restrictions enabled Novo’s practitioners to provide patients with additional in-person services.

The easing of COVID-19 restrictions enabled Novo’s practitioners to provide patients with additional in-person services.

The easing of COVID-19 restrictions enabled Novo’s practitioners to provide patients with additional in-person services.

The easing of COVID-19 restrictions enabled Novo’s practitioners to provide patients with additional in-person services.

The easing of COVID-19 restrictions enabled Novo’s practitioners to provide patients with additional in-person services.

The easing of COVID-19 restrictions enabled Novo’s practitioners to provide patients with additional in-person services.

The easing of COVID-19 restrictions enabled Novo’s practitioners to provide patients with additional in-person services.

The easing of COVID-19 restrictions enabled Novo’s practitioners to provide patients with additional in-person services.

The easing of COVID-19 restrictions enabled Novo’s practitioners to provide patients with additional in-person services.

"This long term study reinforces the efficacy and safety of AZSTARYS as an important treatment option for healthcare professionals to consider when choosing the optimal ADHD therapy for their patients."

I recall an earlier posting last year of the same clinic who said patients were doing well and parents were liking the appetite benefits

$KMPH On the Facebook adhd forums, a mom said her sons doctor has had a few patients on azstarys and has had no complaints.

$KMPH 700 new patients last week I'll take that!

but again given the seasonality of ADHD in early school season combined with the Holidays, imo pretty OK. Actually gained more net new patients then Qelbree. .

However, what I like best is that it is working on actual patients.

Shows a strong base of patients.

Here's to a great 2023 with scripts continuing increasing by 500 plus patients per week, great IH results and submitting to the fda our arimiclomol application

And they are sooo patient

So I am very positive this is a good treatment for me.